from web site

WILMINGTON, Del. & nicorette inhaler --()-- Extab Corporation ("Extab") a medical phase biopharmaceutical company with a focus on smoking cigarettes cessation, today announced the outcomes of an expense effectiveness research study published in the peer examined journal, Nicotine and Tobacco Research. These information are based upon the results of the Tabex Cigarette Smoking Cessation ("TASC") 740-patient essential trial, which were published in the New England Journal of Medicine on September 29, 2011.


Stopped rates were validated by exhaled carbon monoxide gas levels. The trial showed a highly statistically considerable outcome with a Danger Ratio of 3. 4 (p.